Tim M. Mayleben has served on our Board since December 2008.

Mr. Mayleben currently serves as President, CEO, and a director of Esperion Therapeutics, Inc., a pharmaceutical company that specializes in developing and commercializing non-statin, once-daily oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). He has more than a decade of executive leadership roles in the life sciences industry, including former President, CEO, and a director of Vericel Corporation (formerly Aastrom Biosciences), former President, COO, and a director of Virtual Radiologics, Inc. (formerly NightHawk Radiology Holdings, Inc.), and former COO and CFO of the original Esperion, until its acquisition by Pfizer in 2004.

Mr. Mayleben earned an MBA, with distinction, from the J.L. Kellogg Graduate School of Management at Northwestern University, and a BBA from the University of Michigan, Ross School of Business.